/Cencora%20Inc_%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease....
Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.
Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....
Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...
Cencora has significantly outperformed the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.
Despite Cencora's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's future.
/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.
Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine...